- Home
- PLX vs SATX Comparison
PLX vs SATX Comparison
Compare PLX & SATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- SATX
- Stock Information
- Founded
- PLX 1993
- SATX 2012
- Country
- PLX Israel
- SATX Israel
- Employees
- PLX N/A
- SATX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- SATX Radio And Television Broadcasting And Communications Equipment
- Sector
- PLX Health Care
- SATX Technology
- Exchange
- PLX Nasdaq
- SATX Nasdaq
- Market Cap
- PLX 160.2M
- SATX 130.6M
- IPO Year
- PLX 1998
- SATX N/A
- Fundamental
- Price
- PLX $2.33
- SATX $1.44
- Analyst Decision
- PLX
- SATX Strong Buy
- Analyst Count
- PLX 0
- SATX 2
- Target Price
- PLX N/A
- SATX $2.25
- AVG Volume (30 Days)
- PLX 553.9K
- SATX 461.3K
- Earning Date
- PLX 03-13-2025
- SATX 02-14-2025
- Dividend Yield
- PLX N/A
- SATX N/A
- EPS Growth
- PLX N/A
- SATX N/A
- EPS
- PLX N/A
- SATX N/A
- Revenue
- PLX $45,667,000.00
- SATX $10,351,000.00
- Revenue This Year
- PLX N/A
- SATX $80.62
- Revenue Next Year
- PLX $90.00
- SATX N/A
- P/E Ratio
- PLX N/A
- SATX N/A
- Revenue Growth
- PLX N/A
- SATX N/A
- 52 Week Low
- PLX $0.82
- SATX $0.33
- 52 Week High
- PLX $2.36
- SATX $2.39
- Technical
- Relative Strength Index (RSI)
- PLX 78.72
- SATX 52.89
- Support Level
- PLX $2.11
- SATX $1.21
- Resistance Level
- PLX $2.36
- SATX $1.57
- Average True Range (ATR)
- PLX 0.12
- SATX 0.33
- MACD
- PLX 0.00
- SATX -0.04
- Stochastic Oscillator
- PLX 94.23
- SATX 19.63
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About SATX SatixFy Communications Ltd.
SatixFy Communications Ltd develops end-to-end next-generation satellite communications systems, including satellite payloads, user terminals and modems, based on powerful chipsets that it develops in house. Its products include modems that feature Software Defined Radio and Fully Electronically Steered Multi Beam Antennas that support the advanced communications standard DVB-S2X. Geographical presence in U.S, Canada, UK and Other countries. Majority of its company revenue comes from U.S and Canada.